Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612668 | 0.87 | GSR (0.55) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL28000252 | 0.87 | GSR (0.55) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL120692 | 0.87 | DPP8 (0.51) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL31722025 | 0.87 | GSR (0.55) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL14906253 | 0.87 | GSR (0.55) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL11111915 | 0.87 | DPP8 (0.43) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL31126783 | 0.87 | DPP8 (0.46) | DPP8DPP9DPP7GNAI3GNAO1 | |
| SCHEMBL11111912 | 0.86 | FOLH1 (0.48) | DPP8DPP9DPP7DPP4FURIN | |
| SCHEMBL11102541 | 0.86 | FURIN (0.42) | DPP8DPP9DPP7FURIN | |
| SCHEMBL27759901 | 0.85 | SLC15A1 (0.56) | DPP8DPP9DPP7GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611824-B2 | Solid phase TGase-mediated conjugation of antibodies | INNATE PHARMA (FR) | 2020-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611824-B2 | Solid phase TGase-mediated conjugation of antibodies | TGM3, TGM2, TGM6 | DPP8 412/4885DPP9 250/4885DPP7 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.